top of page

Biopharma Daily Stock Updates - 03/16/22

$XBI $86.19 | +4.79%


Covid Updates


Pipeline Updates

$AZN +1.0% Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer source

$ORMP +6.9% Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial. source

$HOWL -2.8% Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment. source

$CLVS +2.1% Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286. source

$ACIU +3.0% AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference. source

$ADAG -0.2% Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab. source

$XERS +4.5% Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above. source

$FOLD +6.2% Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference. source

$KPTI +7.2% Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer. source

$APLS +13.0% Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA). source

$PRTA +7.1% Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022. source

Business Updates



Posted by FS/JM

bottom of page